Form 2022 R2.0: Testicular/Germ Cell Cancer Pre-HSCT Data

Center: CRID:

Key Fields

Registry Use Only

Sequence Number: _____

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number: _____

CIBMTR Recipient ID: _____

Today's Date: __ __ __ __ - __ __- __ __

Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __

HSCT type (check all that apply):

- Autologous
- Allogeneic, unrelated
- Allogeneic, related
- Syngeneic (identical twin)

Product type (check all that apply):

- Marrow
- PBSC
- Cord blood
- Other product

Specify: _____

- If this is a report of a second or subsequent transplant, check here and continue with question 117.

Disease Assessment at Diagnosis

Questions: 1 - 34

1 What was the date of pathologic diagnosis of Testicular Cancer? __ __ __ __ - __ __- __ __

Specify the origin of the primary tumor at diagnosis:

2 Testicular primary

yes no

3 Extra-gonadal germ cell tumor

yes no

Specify site(s) of extra-gonadal germ cell tumor:

4 Abdominal nodes

yes no

5 Bone

yes no

6 Central nervous system (CNS)

yes no

7 Liver

yes no

8 Lung, parenchymal

yes no

9 Mediastinum

yes no

10 Testis

yes no

11 Other site:

yes no

12 Specify tumor site: _____

Specify the testicular cancer histology at diagnosis:

13 Choriocarcinoma

yes no

14 Embryonal carcinoma

yes no

15 Mixed non-seminoma

yes no

16 Seminoma

yes no

17 Teratoma

yes no

18 Yolk sac

yes no

19 Other histology

yes no

20 Specify histology: _____

Specify the tumor mass classification at diagnosis:

21 Seminoma (must have normal levels of alpha-fetoprotein (AFP))

yes no

22 Specify prognosis:

good prognosis - no nonpulmonary visceral metastasis

intermediate prognosis

23 Non-seminoma

yes no

24 Specify prognosis:

good prognosis - requires all of the following: • AFP < 1,000 ng/ml, HCG < 5,000 IU/L, and LDH < 1.5x upper limit of normal • nonmediastinal primary mass • no nonpulmonary visceral metastasis

intermediate prognosis - requires all of the following: • AFP= 1,000-10,000 ng/mL, HCG = 5,000-50,000 IU/L, or LDH = 1.5-10x upper limit of normal • nonmediastinal primary site • no nonpulmonary visceral metastasis

poor prognosis - any of the following: • AFP > 10,000 ng/mL, HGC > 50,000 IU/L, or LDH >10x upper limit of normal • mediastinal primary site • nonpulmonary visceral metastasis present

25 Were extra-gonadal metastases present at diagnosis?

yes no Unknown

Specify site(s) of extra-gonadal metastases present at diagnosis:

26 Central nervous system

yes no

27 Liver

yes no

28 Lung, parenchymal

yes no

29 Lymph nodes, distant

yes no

30 Lymph nodes, retroperitoneal

yes no

31 Pleura

yes no

32 Skin

yes no

33 Other site:

yes no

34 Specify site: _____

Laboratory Studies at Diagnosis

Questions: 35 - 43

Specify the following tumor markers present prior to any first treatment for testicular cancer.

35 Serum alpha-fetoprotein (AFP):

Known Not known

36 _____ ng/mL

37 Serum beta-human chorionic gonadotropin (βhCG):

Known Not known

38 _____ IU/L

39 LDH:

Known Not known

40 _____

U/L μkat/L

41 Other tumor marker?

yes no

42 Specify other tumor marker: _____

43 Specify value: _____

Pre-HSCT Treatment for Testicular Cancer

Questions: 44 - 116

44 Did the recipient undergo surgery as part of the initial disease management plan?

yes no Unknown

Specify surgery type(s) performed:

45 Biopsy only (not debulking)

yes no

46 Debulking

yes no

47 Orchiectomy only

yes no

48 Removal of extra-abdominal metastatic lesion

yes no

49 Unilateral retroperitoneal lymph node dissection and orchiectomy

yes no

50 Other surgery

yes no

51 Specify surgery: _____

Specify the following tumor markers determined after surgery was performed:

52 Serum alpha-fetoprotein (AFP):

Known Not known

53 _____ ng/mL

54 Serum beta-human chorionic gonadotropin (βhCG):

Known Not known

55 _____ IU/L

56 LDH:

Known Not known

57 _____

U/L μkat/L

58 Other tumor marker?

yes no

59 Specify tumor marker: _____

60 Specify value: _____

61 Was tumor staging performed?

yes no

62 Specify the testicular cancer stage:

stage I - cancer remains localized to the testis

stage II - cancer involved the testis and metastasis to retroperitoneal / paraaortic lymph nodes

stage III - the cancer involves the testis and metastasus beyond the retroperitoneal and paraaortic lymph nodes

63 Is a copy of the pathology report attached?

yes no

64 Was therapy given between diagnosis and the start of the preparative regimen? (Include surgery other than the initial surgery and/or neo-adjuvant and adjuvent therapy.)

yes no

Line of Therapy (1) **Questions: 65 - 116**

65 Systemic Therapy:

yes no

66 Date therapy started: __ __ __ __ - __ __- __ __

67 Date therapy stopped: __ __ __ __ - __ __- __ __

68 Number of cycles _____ Unknown/not applicable

69 Was therapy given prior to any surgery (neoadjuvant)?

yes no

70 aldesleukin (interleukin-2)

yes no

71 altretamine (Hexalen)

yes no

72 bleomycin (BLM, Blenoxane)

yes no

73 carboplatin (Paraplatin)

yes no

74 cisplatin (CDDP, Platinol)

yes no

75 cyclophosphamide (CTX)

yes no

76 dactinomycin (Cosmegen)

yes no

77 Doxorubicin (Adriamycin)

yes no

78 Doxorubicin liposomal (Doxil)

yes no

79 Etoposide (VP-16, VePesid)

yes no

80 Gemcitabine (Gemzar)

yes no

81 Ifosfamide (Ifex)

yes no

82 Mitoxantrone (Novantrone)

yes no

83 methotrexate (MTX, Folex)

yes no

84 paclitaxel (Taxol)

yes no

85 thiotepa (Thioplex)

yes no

86 vinblastine (Velban, VLB)

yes no

87 other therapy

yes no

88 Specify other therapy: _____

89 Radiation Therapy:

yes no

90 Date therapy started: __ __ __ __ - __ __- __ __

91 Date therapy stopped: __ __ __ __ - __ __- __ __

92 Local / regional

yes no

93 Specify total dose: _____ cGy (rads)

94 Other radiotherapy site

yes no

95 Specify other radiation site: _____

96 Specify total dose: _____ cGy (rads)

97 Fractionation schedule:

single single daily multiple daily other schedule

98 Surgery (other than initial):

yes no

99 Date of surgery: __ __ __ __ - __ __- __ __

100 Tye of surgery: _____

101 Specify other surgery type: _____

102 Was this line of therapy given for stem cell priming?

yes no

103 Best Response to Line of Therapy:

CCR Continued complete response - continued absence of all disease after a complete response

CR Complete response - absence of clinically detectable disease including normal HCG and AFP and normalization of previously abnormal radiographic studies for at lease one month

PR Partial response - >=50% reduction in the sum of the perpendicular diameters of measureable lessions for >= 1 month and/or >= 50% reduction in tumor markers

SD Stable disease - tumor regression not fulfilling the requirement for partial response or tumor progression < 25% increase in the bidimensionally measurable tumor parameters

NR No response - < 50% reduction in disease or tumor markers

PD Progressive disease - new lesions that prove to be viable cancer and/or rise in the pretreatment tumor markers and/or > 25% increase in measurable lesions that are related to progressive viable cancer

ME Markers elevated - no measurable disease, but tumor markers elevated

NETD Not evaluable, toxic death

NA Not assessed

104 Specify reason: _____

105 Date response evaluated: __ __ __ __ - __ __- __ __

106 Did patient relapse/progress following this line of therapy?

yes no

107 Date of relapse/progression: __ __ __ __ - __ __- __ __

Site(s) of relapse:

108 central nervous system

yes no

109 Liver

yes no

110 lung, parenchymal

yes no

111 lymph nodes, distant

yes no

112 lymph nodes, retroperitoneal

yes no

113 pleura

yes no

114 Skin

yes no

115 other site of relapse

yes no

116 specify other site of relapse _____

Most Recent Disease Assessment Prior to the Start of the Preparative Regimen

Questions: 117 - 140

117 Indicate the sensitivity of the testicular carcinoma to any chemotherapeutic agent administered prior to the preparative regimen:*(Response to last chemotherapy given prior to HSCT; chemotherapy must include ≥ 2 cycles of treatment given ≤ 6 months prior to HSCT.)*

sensitive- ≥ 50% reduction in bidimensional diameter of all disease sites with no new sites of disease; and >= 50% decrease in tumor markers, if evaluated

resistant- <50% reduction in disease or tumor marker evaluation with chemotherapy within 6 months of HSCT

untreated- includes chemotherapy given more than 6 months prior to HSCT, or fewer than 2 treatment cycles

Unknown

118 Indicate the sensitivity of the testicular carcinoma to any platinum-containing chemotherapeutic agent administered prior to the preparative regimen: *(Response to last platinum therapy given prior to HSCT; therapy must include ≥ 2 cycles of treatment given ≤ 6 months prior to HSCT.)*

sensitive - response to platinum with ≥ 50% reduction in bidimensional diameter of all disease sites with no new sites of disease; and > 50% decrease in tumor markers, if elevated *(Note: a non-response to subsequent non-platinum chemotherapy does not affect designation)*

resistant - <50% response to platinum therapy in disease and tumor markers, or relapse <= 6 months after last platinum chemotherapy

untreated

refractory - progression of disease within 4 weeks of last Cisplatin dose

Unknown

Specify the results of any imaging performed for the following disease sites:

Present at any time between diagnosis and HSCT?

119 Abdomen -- CT

yes no Unknown

120 Bone -- bone scan

yes no Unknown

121 Bone -- CT

yes no Unknown

122 Bone -- MRI

yes no Unknown

123 Bone -- x-ray

yes no Unknown

124 Chest -- CT

yes no Unknown

125 Chest -- x-ray

yes no Unknown

126 Head -- CT

yes no Unknown

127 Head -- MRI

yes no Unknown

128 Pelvis -- CT

yes no Unknown

129 PET scan

yes no Unknown

Specify the results of any imaging performed for the following disease sites:

Present immediately prior to the start of the preparative regimen?

130 Abdomen -- CT

yes no Unknown

131 Bone -- bone scan

yes no Unknown

132 Bone -- CT

yes no Unknown

133 Bone -- MRI

yes no Unknown

134 Bone -- x-ray

yes no Unknown

135 Chest -- CT

yes no Unknown

136 Chest -- x-ray

yes no Unknown

137 Head -- CT

yes no Unknown

138 Head -- MRI

yes no Unknown

139 Pelvis -- CT

yes no Unknown

140 PET scan

yes no Unknown

Laboratory Studies Prior to the Start of the Preparative Regimen

Questions: 141 - 149

Specify the following tumor markers determined prior to the preparative regimen:

141 Serum alpha-fetoprotein (AFP):

Known Not known

142 _____ ng/mL

143 Serum beta-human chorionic gonadotropin (βhCG):

Known Not known

144 _____ IU/L

145 LDH:

Known Not known

146 _____

U/L μkat/L

147 Other tumor marker?

yes no

148 Specify other tumor marker: _____

149 Specify value: _____

Disease Status at the Last Assessment Prior to the Preparative Regimen

Questions: 150 - 164

150 Central nervous system

yes no

151 Liver,parenchymal

yes no

152 Lung

yes no

153 Lymph nodes, distant

yes no

154 Lymph nodes, retroperitoneal

yes no

155 Pelvis

yes no

156 Pleura

yes no

157 Tumor markers (AFP, HCG, LDH)

yes no

158 Other site:

yes no

159 Specify other new site: _____

160 Was a prior HSCT performed for testicular cancer?

yes no Unknown

161 Is this HSCT a planned tandem HSCT?

yes no Unknown

162 Is this HSCT in response to residual disease?

yes no Unknown

163 What was the disease status at the last evaluation prior to the preparative regimen?

- no evidence of disease as defined surgically, tumor markers within normal limits
- no evidence of disease as defined clincally, tumor markers within normal limits
- tumor marker elevation only
- residual tumor mass, tumor markers within normal limits
- residual tumor mass, elevated tumor markers
- Not evaluable
- Unknown

164 Date of the most recent assessment for disease status prior to the preparative regimen: __ __ __ __ - __ __- __ __

First Name: _____ Last Name: _____

Phone: _____ Fax: _____

E-mail address: _____